Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Vandoeuvre Les Nancy – page 8

587 clinical trials in Vandoeuvre Les Nancy, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Vandoeuvre Les Nancy at a glance
587
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

587 trials in Vandoeuvre Les Nancy

Open in trial search

Craniocerebral injury

Recruiting

Study of hypertonic saline solution and mannitol to improve recovery in patients with traumatic brain injury and high risk of intracranial hypertension

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Mannitol
  • Sponsor:Centre Hospitalier Universitaire De Nantes

Breast cancer

Recruiting

Evaluating elacestrant alone or with leuprorelin in premenopausal women with early-stage hormone receptor positive breast cancer before surgery

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Leuprorelin Acetate
  • Sponsor:Institut Gustave Roussy

Neoplasm malignant

Recruiting

Study of BMS-986504 for patients with advanced or metastatic non-small cell lung cancer with homozygous MTAP deletion who have previously received treatment

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:2-[4-[4-(AMINOMETHYL)-1-OXO-2H-PHTHALAZIN-6-YL]-2-METHYLPYRAZOL-3-YL]-4-CHLORO-6-CYCLOPROPYLOXY-3-FLUOROBENZONITRILE
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Squamous cell carcinoma of head and neck

Recruiting

Study of ficerafusp alfa and pembrolizumab as first treatment for patients with PD-L1-positive recurrent or metastatic head and neck cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Bicara Therapeutics Inc.

HER2 positive breast cancer

Recruiting

Study evaluating HER2DX-guided treatment in patients with early-stage HER2-positive breast cancer using trastuzumab, pertuzumab and combination chemotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer

Gastric cancer stage IV+1

Recruiting

Study of ivonescimab with chemotherapy combination for first and second-line treatment in patients with advanced or metastatic gastric and gastroesophageal cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Levofolinate
  • Sponsor:Unicancer

Renal transplant

Recruiting

Study of immunosuppression reduction in kidney transplant patients with septic shock or respiratory failure receiving drug combination therapy in intensive care

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azathioprine
  • Sponsor:Les Hopitaux Universitaires De Strasbourg

Endocarditis staphylococcal

Recruiting

Comparing rifampin-free treatment versus rifampin in adults with staphylococcal prosthetic valve endocarditis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cefazolin Sodium
  • Sponsor:Centre Hospitalier Universitaire De Nantes

K-ras gene mutation+1

Recruiting

Study of MK-1084, cetuximab and mFOLFOX6 combination compared to mFOLFOX6 with or without bevacizumab for patients with KRAS G12C-mutant advanced colorectal cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Merck Sharp & Dohme LLC

Fallopian tube cancer+1

Recruiting

Study of mirvetuximab soravtansine dosing schedules for patients with platinum-resistant advanced ovarian, peritoneal, or fallopian tube cancer with high folate receptor expression

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Prednisolone Acetate
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

B-cell small lymphocytic lymphoma refractory+1

Recruiting

Study of sonrotoclax plus obinutuzumab or rituximab compared to venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:BeOne Medicines AG

Transitional cell carcinoma

Recruiting

Study of datopotamab deruxtecan with platinum-based therapy compared to gemcitabine with platinum-based therapy in patients with advanced urothelial cancer after prior treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Daiichi Sankyo Inc.

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Vandoeuvre Les Nancy

What the registry says about research in the country

01 Oncology Research

Clinical trials focusing on innovative treatments for various cancer types, including head and neck squamous cell carcinoma, multiple myeloma, and prostate cancer. Studies evaluate new therapeutic approaches and diagnostic methods.

  • Advanced cancer treatments
  • Therapeutic combinations
  • Survival outcomes

Several trials investigate novel drug combinations and targeted therapies for improving patient outcomes.

02 Autoimmune Conditions

Comprehensive research into inflammatory bowel diseases, particularly Crohn's disease and ulcerative colitis. Studies explore innovative treatments including microbiota transplantation and new biological therapies.

  • Disease management
  • Treatment efficacy
  • Long-term outcomes

Trials aim to develop more effective maintenance therapies and improve quality of life for patients.

03 Neurological Disorders

Groundbreaking research in multiple sclerosis treatment, including both progressive and relapsing forms. Studies evaluate new therapeutic approaches and disease progression markers.

  • Disease modification
  • Treatment safety
  • Clinical outcomes

Focus on developing innovative treatments for better management of neurological conditions.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.